Roslin Technologies embarks on Series B Acceleration Funding to Expand Globally

August 21, 2020

BY Alexander Kalis

– For Professional Investors Only –

Milltrust International is pleased to share an exciting opportunity to co-invest with us into the UK’s largest-ever Agriscience start-up, which we seeded back in 2016.

In 2016, our British Innovation Fund made a landmark investment alongside JBI Equity (Hong Kong) into Roslin Technologies, a spin-out of the world-renowned Roslin Institute at the University of Edinburgh, famous for its pioneering work which led to the birth of Dolly the Sheep some years earlier.

Roslin Technologies, the commercialisation vehicle for much of the ground-breaking science from the Institute and the Royal (Dick) School of Veterinary Studies, is now seeking to raise a Series B funding round of at least £50m, at a pre-money valuation of £57m, a valuation that was independently arrived at by MAZARS.

Roslin Technologies is based in Edinburgh’s Midlothian Science Zone, the largest single concentration of animal science in Europe. The company is developing pioneering solutions in the AgriFood space to sustainably and safely meet the food needs of a rapidly expanding global population. By 2030, the markets Roslin Tech focuses on are forecast to have a combined value of over $260bn.

The company has an exclusive commercial partnership with the Roslin Institute and Royal (Dick) School, with first right of refusal on all unencumbered IP emanating from the world-class research conducted at these institutions. Further, Roslin has a broad scope to build partnerships around the world investing in both capital and expertise. To date this unique venture builder had focused on the following lines:

  • Bespoke breeding programmes – for product enhancement, including genetic evaluations for livestock, and projects well advanced in the production of alternative protein from insects and shrimp (Insect protein will be a huge source of future animal feed, as well as a means of bioconversion as insects feed on organic bi-products such as fruit husks or dairy effluents);
  • Animal cells – Roslin’s unique technology allows the creation of bespoke cell-lines. Key focus is on the production of Clean Meat and development of multi-species cell line production; and
  • Animal health – cutting-edge health-tech / disease research providing diagnostics, vaccine and reagent solutions for a healthier and safer food supply chain.

The capital raise will provide acceleration funding for each of these portfolio lines as the company expands globally across these areas, resulting in a rapid increase in revenue and EBITDA (EBITDA of >£37m forecast for y/e 2025).

Contact us for more information

Glen Illing

Beyond Dolly the sheep: The Roslin Institute

Important Disclaimer

For professional investors only. This communication is strictly private and confidential and is meant as guidance and information only. It is issued by Milltrust International LLP incorporated in the United Kingdom, which is authorised and regulated by the Financial Conduct Authority. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. Milltrust Agricultural Investments Ltd is an affiliate of Milltrust International LLP. The content in this document is for informational purposes only and does not constitute legal, tax, investment, financial, or other advice. Nothing contained in this document constitutes a solicitation, recommendation, endorsement, or offer by Milltrust International LLP or any of its affiliates to buy or sell any securities or other financial instruments. No such solicitation or offer is made in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. All content in this document is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the document constitutes professional and/or financial advice, nor does any information on the document constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. It should therefore not be used as the sole basis for any investment or other decision. The use of or access to this document or content by any person does not create a fiduciary relationship between such person and Milltrust International LLP. The sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this communication before making any decisions based on such information or other content rests with the user and their professional advisers.